CTRI/2024/06/068637尚未招募2 期
A randomized, double blinded, two arm, parallel group, placebo controlled clinical study toevaluate the effect of 250 mg water dispersible Turmeric extract capsules (TurmXTRA60N) on facial skin parameters and its in-use tolerance in healthy adult women participants. - NI
utriventia Limited Unit0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Healthy women participants from 18-40 years of age declared healthy after assessing
- •medical history, physical examination and clinical judgment of the investigator.
- •2. Presence of blemish on face (Post inflammatory hyperpigmentation, acne marks, age
- •spots, sun spots) with otherwise healthy skin on the test area.
- •3. Willingness to discontinue the use of other cosmetic products on face during the course
- •of the study.
- •4. Accepting not to use topical or / and oral products with the same end benefit or products
- •containing sunscreen which might interfere with the study results, during the entire study
- •5. Cooperating, informed of the need and duration of the examinations, and ready to comply
- •with protocol procedures.
- •6. Having signed a Consent Form, after being informed orally and in writing of all
- •information concerning the study procedures and study objectives.
- •7. Willingness to avoid intense UV exposure as far as possible for the entire study duration.
- •8. Results of screening test are within normal range or considered not clinically significant
- •by the principal Investigator.
排除标准
- •1. Male participants.
- •2. Peri-menopausal and post-menopausal women.
- •3. Pregnant women as confirmed by UPT or lactating women.
- •4. Presence of any cutaneous conditions on test site (scars, moles, papules etc).
- •5. Presence of any clinically significant systemic or cutaneous disease, which may interfere
- •with study treatments or procedures.
- •6. History or presence of substance abuse (alcohol, drugs, smoking).
- •7. Subject likely to undergo any surgery during the period of the study or within 01 month
- •of study completion.
- •8. Participation in any other experimental Investigational study within last 1 month as
- •identified during screening on visit 1 (V1).
- •9. Presence of any hard damage to skin (e.g., excessive sunburn or suntan).
- •10. History of use of collagen peptide containing supplement in the past 6 months.
- •11. History of consumption of high doses of vitamin C (>500 mg a day) or any other high
- •dose antioxidant product in the past 1 month.
- •12. Subjects on any nutritional supplement or consuming any therapeutic medication for any
- •disorder for last 45 days.
- •13. Subjects with known allergies to any of the ingredients of the study products
- •14. Individuals with chronic gastrointestinal issues such as frequent indigestion, GERD.
- •15. Subjects with severe acne.
- •16. Subjects with the history of gallstones or bile duct obstruction disorders.
- •17. Subjects with the history of bleeding disorders.
- •18. Difficulty in swallowing and retaining oral formulation.
- •19. Any history of difficulty in accessing veins to draw blood.
研究者
相似试验
尚未招募
1 期
Comparative PK, PD and Immunogenicity Study of ADL-018 Lyophilized Powder With Xolair XOLAIR Lyophilized Powder.CTRI/2022/08/045092Kashiv BioSciences LLC
进行中（未招募）
1 期
A clinical trial to evaluate the safety and the efficacy of a combination of Rupatadine and Montelukast compared to Rupatadine in patients with Allergic RhinitisModerate to severe seasonal allergic rhinitis with and without mild to moderate bronchial asthmaMedDRA version: 21.1Level: LLTClassification code 10001723Term: Allergic rhinitisSystem Organ Class: 100000004855EUCTR2020-005135-73-PLBiohorm, S.L.300
进行中（未招募）
1 期
A clinical trial to evaluate the safety and the efficacy of a combination of Rupatadine and Montelukast compared to Rupatadine in patients with Allergic RhinitisSeasonal allergic rhinitis with and without mild to moderate bronchial asthmaMedDRA version: 21.1Level: LLTClassification code 10001723Term: Allergic rhinitisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2020-005135-73-BGBiohorm, S.L.300
已完成
Unknown
A clinical study to check the safety and effectiveness of Anti-Ageing and skin brightening gel in healthy adult female subjects.CTRI/2023/09/057287Green Mountain Biotech Limited44
已完成
不适用
Rhinothermy in the Common Cold (RiCC)Common coldACTRN12617001340325Fisher & Paykel Healthcare Limited170